For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Moderna Inc (NASDAQ: MRNA) closed at $57.73 in the last session, down -0.96% from day before closing price of $58.29. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 3.34 million shares were traded. MRNA stock price reached its highest trading level at $58.96 during the session, while it also had its lowest trading level at $57.05.
Ratios:
We take a closer look at MRNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.92 and its Current Ratio is at 4.09. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
On September 13, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $88 to $70.
Jefferies Downgraded its Buy to Hold on September 13, 2024, whereas the target price for the stock was revised from $120 to $65.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 07 ’24 when Mock James M sold 715 shares for $60.12 per share. The transaction valued at 42,986 led to the insider holds 9,505 shares of the business.
Klinger Shannon Thyme sold 551 shares of MRNA for $40,539 on Sep 09 ’24. The Chief Legal Officer now owns 18,154 shares after completing the transaction at $73.57 per share. On Sep 09 ’24, another insider, Klinger Shannon Thyme, who serves as the Officer of the company, bought 551 shares for $73.57 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 22406455296 and an Enterprise Value of 14972182528. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.40 while its Price-to-Book (P/B) ratio in mrq is 1.89. Its current Enterprise Value per Revenue stands at 2.965 whereas that against EBITDA is -3.646.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $55.70. The 50-Day Moving Average of the stock is -20.98%, while the 200-Day Moving Average is calculated to be -44.47%.
Shares Statistics:
According to the various share statistics, MRNA traded on average about 4.77M shares per day over the past 3-months and 4552050 shares per day over the past 10 days. A total of 382.00M shares are outstanding, with a floating share count of 342.76M. Insiders hold about 10.83% of the company’s shares, while institutions hold 67.93% stake in the company. Shares short for MRNA as of 1727654400 were 31324987 with a Short Ratio of 6.57, compared to 1724976000 on 25632195. Therefore, it implies a Short% of Shares Outstanding of 31324987 and a Short% of Float of 10.7200004.
